Advantages:

To compare the effectiveness of intravitreal triamcinolone and bevacizumab injections combined with grid laser photocoagulation for macular edema due to branch retinal vein occlusion.

Methods:

Retrospective, comparative, interventional clinical study. 37 patients with macular edema due to branch retinal vein occlusion treated with intravitreal triamcinolone acetonide injection combined with grid laser photocoagulation and 18 patients with intravitreal bevacizumab injection combined with grid laser photocoagulation. Main outcome measures were changes in best-corrected visual acuity and central retinal thickness from baseline to the last follow up visit.

Results:

Mean follow-up time was 31 ±22.1 months (ranging between 7-83 months) in triamcinolone acetonide group and 23.2 ±15.8 months (ranging between 7-58 months) in bevacizumab group. Mean number of injections was 1.6 ±0.8 (ranging between 1-4) in triamcinolone acetonide group and 1.7 ±5.5 (ranging between 1-4) injection. The best-corrected visual acuity improvement was 1.1 LogMAR line in triamcinolone group and 1.5 LogMAR line in bevacizumab group. Mean reduction of central retinal thickness was 180 microns and 221 microns in triamcinolone and bevacizumab groups, respectively. Complications were limited with secondary glaucoma and cataract formation in triamcinolone group and epimacular membrane formation in both groups.

Conclusion:

Intravitreal injection of triamcinolone and bevacizumab combined with grid laser photocoagulation have nearly the same efficacy on macular edema due to branch retinal vein occlusion.